000 01328 a2200409 4500
005 20250517050410.0
264 0 _c20151209
008 201512s 0 0 eng d
022 _a1873-3468
024 7 _a10.1016/j.febslet.2015.07.052
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aGschwandtner, Martha
245 0 0 _aGlycosaminoglycan silencing by engineered CXCL12 variants.
_h[electronic resource]
260 _bFEBS letters
_cSep 2015
300 _a2819-24 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAnimals
650 0 4 _aCell Line, Tumor
650 0 4 _aChemokine CXCL12
_xgenetics
650 0 4 _aFemale
650 0 4 _aGene Silencing
650 0 4 _aGlycosaminoglycans
_xdeficiency
650 0 4 _aHumans
650 0 4 _aLiver
_xpathology
650 0 4 _aMice
650 0 4 _aMutation
650 0 4 _aProtein Engineering
650 0 4 _aReceptors, G-Protein-Coupled
_xmetabolism
650 0 4 _aSignal Transduction
_xgenetics
700 1 _aTrinker, Martin U
700 1 _aHecher, Bianca
700 1 _aAdage, Tiziana
700 1 _aAli, Simi
700 1 _aKungl, Andreas J
773 0 _tFEBS letters
_gvol. 589
_gno. 19 Pt B
_gp. 2819-24
856 4 0 _uhttps://doi.org/10.1016/j.febslet.2015.07.052
_zAvailable from publisher's website
999 _c25192676
_d25192676